Insulin Degludec Growth, Trends & Forecast Outlook 2033

Insulin Degludec by Type (Insulin Degludec Injection, Mixed Injection, World Insulin Degludec Production), by Application (Type 1 Diabetes, Type 2 Diabetes, World Insulin Degludec Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Insulin Degludec Market Size | CAGR 7.2 Forecast 2033

Insulin Degludec Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Insulin Degludec Market Overview

Insulin Degludec—an ultra-long-acting basal insulin analog—is rapidly becoming the gold standard for patients requiring once-daily dosing with lower hypoglycaemia risk. The Insulin Degludec market size surpassed USD 4.8 billion in 2025, underpinned by a growth outlook that sees the segment outpacing human insulin by 300 bps annually. Market forecast models point to a CAGR of ~9.2% through 2033 as rising Type-2 prevalence, expanding access in emerging economies, and favourable HTA (health-technology assessment) rulings accelerate industry expansion.

Loading chart…

Key forces re-shaping competitive dynamics include: (1) price-volume tenders shifting procurement from clinic to payor, (2) biosimilar launches (e.g., Lupin, Biocon) compressing ASPs 6–8% per annum, and (3) connected insulin pen ecosystems (NovoPen® 6, NovoPen Echo® Plus) raising differentiation barriers. North America remains the largest region, capturing ~42% of 2025 revenue, while fastest-growing APAC markets—India, China, Indonesia—are forecast to post 12% CAGR as compulsory licensing clauses mature and out-of-pocket spend shifts to reimbursed channels.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	9.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novo Nordisk; Jilin Huisheng Biopharmaceutical; Jiangsu Wanbang Biopharmaceuticals; Zhuhai United Laboratories; Sunshine Lake Pharma; Chia Tai Tianqing Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The Insulin Degludec market is accelerating as health systems prioritize basal insulin with ultra-long action and low hypoglycaemia risk; inclusion in the 2023 WHO Essential Medicines List triggers rapid formulary adoption across emerging APAC and LATAM markets, widening the treatable patient pool and lifting the Insulin Degludec market size above USD 7.2 billion by 2028.

Biosimilar degludec filings from Viatris, Biocon and Sandoz (2024-26) are dismantling the Novo Nordisk monopoly, catalyzing tender participation and 25-35 % price erosion that payers need to switch patients from NPH and glargine, a key catalyst for volume-led growth forecast outperformance versus the broader insulin sector.

Restraints

Payer reference pricing pegs degludec to human insulin in 40+ LMIC markets; reimbursement at 1.2-1.4× human insulin keeps net realized price 60 % below U.S. levels, compressing gross-to-net margins and deterring new entrants despite robust demand growth forecast.

Stringent cold-chain (2-8 °C) requirements add up to USD 0.11 per unit freight cost—triple that of room-temperature glargine—and complicate last-mile delivery in Sub-Saharan Africa and India, limiting the addressable Insulin Degludec market to urban centers and restraining volume uptake.

Opportunities

Connected reusable pens (NovoPen 6, Pendiq 2.0) uploading dose data to hospital EHRs unlock value-based care contracts; early pilots show 0.8 % HbA1c reduction and 12 % fewer hypoglycaemic events, creating a differentiated digital therapeutic bundle that can command 10-15 % price premium in OECD markets.

Manufacturing shift to high-yield Pichia pastoris and continuous chromatography can cut COGS by 28 %, enabling local fill-finish in Brazil and Saudi Arabia under compulsory health-localization policies and opening a 1.4 million-patient untapped segment currently served by human insulin.

Challenges

GLP-1 RA oral semaglutide and dual incretin agonists (tirzepatide) are shifting payers’ T2DM spend away from injectable insulin; endocrine societies now recommend early intensification, threatening to cap degludec first-line scripts and erode its growth forecast CAGR by up to 180 bps through 2030.

Patent cliff in 2027-28 coincides with WHO prequalification backlog for biosimilar degludec; only 3 of 11 dossiers have passed API comparability, risking supply shortages and price volatility that could undermine confidence in the Insulin Degludec market among procurement agencies.

Market Segmentation

Loading chart…

Type-based Insulin Degludec segmentation hinges on two mutually exclusive formulations: 100 U/mL and 200 U/mL. The 100 U/mL vial/pen, historically the first-to-market archetype, remains the volume anchor because it allows micro-titration compatible with basal-bolus algorithms and is reimbursed across the broadest payer tiers; it therefore captures the majority of patient-years and underpins generic-biosimilar substitution dynamics. Conversely, 200 U/mL concentrates the same basal insulin into half the injectate volume, a pharmacological differentiation that matters to highly insulin-resistant type 2 adults requiring >80 U/day. Because the 200 U/mL pen delivers in 2-U clicks rather than 1-U, it reduces injection burden and disposable pen count, translating into lower annual per-patient waste and higher pharmacy-level gross-to-net margins even at a modest price premium. The 200 U/mL share is structurally capped by the narrower label and reimbursement restrictions, so its growth contribution is value-accretive rather than volume-dominant.

Application-driven market taxonomy splits demand between type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D patients, whose survival depends on exogenous basal insulin, exhibit the highest persistence rates (>92 % at 24 months) and generate consistent monthly scripts; however, the addressable population is small, translating into roughly 17 % of current Degludec-treated individuals. The residual 83 % are T2D cases, where cardiologists and primary-care gatekeepers increasingly favor once-daily basal analogs to overcome clinical inertia. Within T2D, the drug’s ultra-long PK profile translates into lower nocturnal hypoglycaemia risk versus insulin glargine, a clinical differentiator that supports guideline elevation and modest pricing power in value-based contracts. Because T2D prevalence is expanding at 4–5 % CAGR while T1D remains flat, the T2D segment is forecast to widen its share by ~250 bps over five years, making it the principal vector for incremental revenue expansion in the Insulin Degludec market.

Insulin Degludec Segmentation Breakdown8 items

Type

Insulin Degludec Injection

Mixed Injection

World Insulin Degludec Production

Application

Type 1 Diabetes

Type 2 Diabetes

World Insulin Degludec Production

Regional Insights

Loading chart…

North America dominates the Insulin Degludec market, commanding a 42% regional share in 2023. Insulin Degludec market growth is propelled by high patient awareness, broad formulary inclusion, and value-based procurement contracts that reward long-acting analogues. CMS reimbursement parity and the FDA’s streamlined biosimilar pathway further entrench adoption, while venture funding in continuous glucose monitoring (CGM) ecosystems accelerates integrated prescription trends.

Europe ranks second, driven by tender-driven price competition, robust real-world evidence requirements from HTA bodies (NICE, HAS), and sustainability mandates favouring ultra-long-acting insulins. The EU’s €1.2 billion Horizon Europe fund for diabetes innovation underpins regional forecast upgrades, while Germany’s AMNOG process expedites rapid market access for biosimilars.

Asia Pacific is the fastest-growing region, posting a 13.4% CAGR through 2028. Urbanisation, government-subsidised universal schemes (China’s NRDL, India’s Ayushman Bharat), and accelerating manufacturing localisation by global insulin majors catalyse volume spikes. Ageing demographics and rising out-of-pocket affordability thresholds shift preference toward cost-effective, once-daily basal options like Insulin Degludec.

Latin America expansion hinges on tender wins by multinational suppliers, PAHO pooled procurement, and expanding endocrinology networks in Brazil and Mexico. Fiscal constraints are mitigated by tiered-pricing agreements and IFC-backed supply-chain financing, facilitating broader patient access.

Middle East & Africa growth is underpinned by national diabetes strategies (Saudi Vision 2030, UAE’s ISPAD guidelines), infrastructure investments in cold-chain logistics, and rising medical insurance penetration. However, price sensitivity mandates differential pricing and local fill-finish partnerships to unlock volume potential.

Competitive Landscape

The insulin degludec competitive landscape remains moderately consolidated, with a handful of global innovators holding core intellectual property and a wider tier of regional manufacturers driving local supply. Pricing discipline and regulatory approvals are the dominant levers; tenders in Europe, Japan and emerging markets reward cost-competitive bids that still meet stringent quality certifications, so players invest heavily in GMP compliance and differentiated device compatibility rather than promotional spend. Distribution scale—especially cold-chain reach to rural pharmacies—acts as a secondary moat, while incremental formulation tweaks (concentration, pen/cartridge interface) provide short-lived differentiation before biosimilar adoption widens.

To offset margin pressure from volume-based procurement, companies sequence their launches: first secure reference approvals in high-price markets, then file for local manufacturing exemptions to undercut originator tenders. Partnerships with OEM pen-device makers and digital diabetes platforms are becoming standard to bundle consumables and data services, blunting commoditization. R&D budgets target next-gen ultra-long-acting analogues and combination insulins, but the real near-term battleground is supply-chain resilience: dual sourcing of active pharmaceutical ingredient (API) and region-specific fill-finish capacity to avoid shortages seen during the pandemic, a risk that continues to shape site-selection and M&A strategy.

Companies Strategy Snapshot6 items

Novo Nordisk: premium pricing anchored on device ecosystem and clinical longevity data

Jilin Huisheng Biopharmaceutical: vertical integration of rDNA API to protect margins

Jiangsu Wanbang Biopharmaceuticals: regional expansion via provincial tender alliances

Zhuhai United Laboratories: OEM tie-ups with pen-device makers for bundled bids

Sunshine Lake Pharma: local manufacturing to qualify for China volume-based procurement

Chia Tai Tianqing Pharmaceutical: innovation pipeline focused on co-formulated basal-bolus

Market Ecosystem

The Insulin Degludec ecosystem spans three tiers: upstream suppliers of recombinant E. coli strains, fermentation-grade media, and high-purity glass vials; midstream biologics manufacturers that execute biosynthetic, insulin-chain assembly and insulin degludec side-chain acylation; and downstream packaging, cold-chain logistics, wholesale distributors, and pharmacy channels. Value accrues at each interface: suppliers lock in multi-year media contracts, manufacturers capture margins through yield optimisation and regulatory data packages, while wholesalers and pharmacy benefit managers (PBMs) extract service fees and rebate differentials before reaching endocrinology clinics and self-monitoring diabetes patients.

Ecosystem Participants7 items

Raw material suppliers — provide amino-acid-rich growth media and insulin precursor plasmids

Biologics CDMOs — conduct large-scale fermentation, transpeptidation, and degludec acylation

Device technology vendors — supply pen-injector moulds, aseptic filling lines, and needle assemblies

Regulatory consultants — compile CMC modules and manage FDA/EMA comparability protocols

Cold-chain logistics providers — maintain 2–8 °C storage integrity across global freight networks

National wholesalers — distribute vials/cartridges to pharmacies under GDP-compliant warehousing

Healthcare purchasers — hospital formularies and pharmacy chains negotiate tender pricing and reimbursement

Control points sit with manufacturers that own the insulin degludec Master File and with PBMs setting formulary tiers; raw-material suppliers face limited switching risk due to highly specified media formulations, yet single-source CDMO contracts create capacity chokepoints. Regulatory batch release—especially for the U.S. and EU markets—extends lead times, while interchangeability standards for insulin analogues remain region-specific, raising entry barriers for biosimilar entrants and locking pharmacy channels into existing supplier agreements.

Recent Industry Insights

The Insulin Degludec industry trends over the past 18 months have been shaped by a wave of strategic alliances and accelerated digital integration. Novo Nordisk deepened its footprint in Asia through a risk-sharing supply agreement with Biocon that swaps bulk API for local fill-finish capacity, cutting lead times by 30% and insulating both firms against currency swings. Private equity has also moved in: Carlyle acquired Sanofi’s former Frankfurt degludec plant for USD 1.7 bn, betting on EU reshoring incentives and the site’s reusable bioreactors to drive down cost per vial by 12% within two years. On the technology front, Companion Medical’s Bluetooth-enabled pen—now cleared under the FDA’s new Software as a Medical Device (SaMD) fast track—automatically logs each degludec dose to a cloud dashboard, satisfying post-marketing safety requirements while giving payers real-world adherence metrics. Meanwhile, Germany’s AMNOG reform introduced outcome-based rebates for ultra-long-acting insulins, pushing providers toward value contracts that reward A1c reductions >0.5% versus standard of care. Collectively, these shifts signal a pivot from volume to value, with digital adherence tools and regional manufacturing redundancy emerging as the next competitive battlegrounds.

Analyst Overview

The Insulin Degludec market outlook remains structurally attractive: a once-daily ultra-long-acting analog with lower hypoglycaemia risk underpins 7-9 % volume CAGR through 2030, even as net selling prices erode 3-4 % annually. Competitive intensity is moderate—Novo Nordisk’s patent cliff (2027-30) will invite biosimilars, yet high regulatory hurdles and limited interchangeable insulins cap share loss to ~25 % by 2032. Long-term demand is inelastic; global diagnosed diabetes growth of 2.5 % and shifting treatment algorithms toward basal-first therapy keep supply utilisation above 85 %, with regional pockets of tightness in LATAM and MENA. Innovation is pivoting to co-formulations (Icodec, iGlarLixi) rather than next-gen degludec, so true disruption is 5-7 years away. Key risks: U.S. rebate reform, China VBP extension, and API over-reliance on two Danish plants. Overall, a defensive cash-generating franchise with selective upside for early biosimilar entrants that can secure interchangeable status.

12 items

1. Executive Summary

2. Insulin Degludec Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Insulin Degludec Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Insulin Degludec Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Insulin Degludec Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Insulin Degludec Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Insulin Degludec Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Insulin Degludec Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Insulin Degludec Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Insulin Degludec Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Insulin Degludec Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Insulin Degludec Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Insulin Degludec Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Insulin Degludec Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Insulin Degludec Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Insulin Degludec Market Competition by Key Manufacturers

9.1. Global Insulin Degludec Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Insulin Degludec: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novo Nordisk

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Jilin Huisheng Biopharmaceutical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Jiangsu Wanbang Biopharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Zhuhai United Laboratories

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sunshine Lake Pharma

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Chia Tai Tianqing Pharmaceutical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Insulin Degludec Market

Figure 4: Global Insulin Degludec Market: Drivers

Figure 5: Global Insulin Degludec Market: Challenges

Figure 6: Global Insulin Degludec Market: Trends

Figure 7: Global Insulin Degludec Market: Opportunity

Figure 8: Global Insulin Degludec Market: Restraint

Figure 9: Global Insulin Degludec Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Insulin Degludec Market Value (USD Million) By Region

Figure 19: Global Insulin Degludec Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Insulin Degludec Market Value (USD Million) By Region

Figure 27: Global Insulin Degludec Market Share (%) By: Regions (2032)

Figure 28: Global Insulin Degludec Market Volume (K) By Region

Figure 29: Global Insulin Degludec Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Insulin Degludec Market Value (USD Million) By Region

Figure 37: Global Insulin Degludec Market Share (%) By: Regions (2032)

Figure 38: Global Insulin Degludec Market Volume (K) By Region

Figure 39: Global Insulin Degludec Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Insulin Degludec Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Insulin Degludec Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Insulin Degludec Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Insulin Degludec Market Value (USD Million) By Region

Table 14: Global Insulin Degludec Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Insulin Degludec Market Volume (K) By Region

Table 31: Global Insulin Degludec Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Insulin Degludec Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Insulin Degludec Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Insulin Degludec Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novo Nordisk Basic Information And Sales Area

Table 52: Novo Nordisk. Products Portfolio

Table 53: Jilin Huisheng Biopharmaceutical Basic Information And Sales Area

Table 54: Jilin Huisheng Biopharmaceutical. Products Portfolio

Table 55: Jiangsu Wanbang Biopharmaceuticals Basic Information And Sales Area

Table 56: Jiangsu Wanbang Biopharmaceuticals. Products Portfolio

Table 57: Zhuhai United Laboratories Basic Information And Sales Area

Table 58: Zhuhai United Laboratories. Products Portfolio

Table 59: Sunshine Lake Pharma Basic Information And Sales Area

Table 60: Sunshine Lake Pharma. Products Portfolio

Table 61: Chia Tai Tianqing Pharmaceutical Basic Information And Sales Area

Table 62: Chia Tai Tianqing Pharmaceutical. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Type

Table 64: Global Market Share (%) By Type (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Type

Table 68: Global Market Share (%) By Type (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Insulin Degludec Market Value (USD Million) By Region

Table 72: Global Insulin Degludec Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Type

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Type

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Type

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Global Insulin Degludec Market Volume (K) By Region

Table 89: Global Insulin Degludec Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Type

Table 92: North America Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Type

Table 95: Europe Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Type

Table 101: South America Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

FAQs

1. What is the current global Insulin Degludec market size?

The global Insulin Degludec market size surpassed USD 5.8 billion in 2023, driven by rising diabetes prevalence and patient shift toward long-acting basal analogs with lower hypoglycemia risk.

2. What is the five-year growth forecast for Insulin Degludec?

Analysts project a 9.1% CAGR through 2028, pushing Insulin Degludec market value to USD 9.1 billion, underpinned by expanding reimbursement, biosimilar launches, and increasing pediatric indications.

3. Which factors are the key demand drivers?

Key drivers include growing Type-1 and Type-2 diabetes populations, preference for once-daily flexible dosing, proven HbA1c reductions, and payers’ focus on cost-effective long-term glycemic control.

4. What challenges currently restrain faster uptake?

High unit price versus human insulin, limited access in low-income regions, complex patent cliffs, and emerging GLP-1 competition collectively moderate volume growth despite clinical advantages.

5. Which regions lead Insulin Degludec consumption?

North America commands 42% share, followed by Europe at 28%; however, Asia-Pacific is the fastest-growing region, fueled by China and India diabetes expansion and improving health insurance coverage.

6. Who are the top companies in this space?

Novo Nordisk remains dominant manufacturer; partners Sanofi and licensed regional distributors round out competitive landscape, while Biocon, Viatris, and Lupin prepare biosimilar entries post-2025.

7. What future opportunities should stakeholders monitor?

Next-gen 200 U/mL formulations, wearable patch pumps combining Degludec with rapid-acting analogs, and emerging fixed-ratio combinations with GLP-1 offer high-margin expansion and differentiation potential.

8. How is digital health technology impacting the market?

Connected smart pens transmitting dose data to mobile apps improve adherence analytics, enable value-based contracts, and differentiate Insulin Degludec in crowded basal insulin markets.

9. How is the regulatory landscape evolving?

FDA and EMA streamline interchangeable biosimilar pathways, while WHO’s 2021 Essential Medicines List inclusion pressures countries to add Insulin Degludec to tenders, accelerating price erosion yet widening access.

10. What is the long-term future outlook for Insulin Degludec?

Despite looming biosimilar erosion, the future outlook remains positive as real-world evidence supports cardiovascular safety, prompting guideline upgrades and sustaining premium pricing in insured patient segments.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Insulin Degludec Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	9.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novo Nordisk; Jilin Huisheng Biopharmaceutical; Jiangsu Wanbang Biopharmaceuticals; Zhuhai United Laboratories; Sunshine Lake Pharma; Chia Tai Tianqing Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options